{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:35:00Z","timestamp":1788690900312,"version":"build-2803163510"},"reference-count":87,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.eprac.2024.11.017","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T16:38:44Z","timestamp":1734453524000},"page":"521-535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Protein-2 Inhibitors on Treating Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials"],"prefix":"10.1016","volume":"31","author":[{"given":"Ruhan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2340-6727","authenticated-orcid":false,"given":"Xianghai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eprac.2024.11.017_bib1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2024.11.017_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.017_bib3","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A\u00a0multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.017_bib4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus","volume":"14","author":"Targher","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2024.11.017_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2024.11.017_bib6","article-title":"First US drug approved for a liver disease surging around the world","author":"Ledford","year":"2024","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2024.11.017_bib7","first-page":"S46","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2024.11.017_bib8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2024.11.017_bib9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2024.11.017_bib10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A\u00a0prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2024.11.017_bib11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A\u00a0global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"10.1016\/j.eprac.2024.11.017_bib12","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A\u00a0placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2024.11.017_bib13","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.eprac.2024.11.017_bib14","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/cam4.1354","article-title":"Pioglitazone and bladder cancer risk: a systematic review and meta-analysis","volume":"7","author":"Tang","year":"2018","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.eprac.2024.11.017_bib15","first-page":"914","article-title":"Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial","volume":"102","author":"Viscoli","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"12","key":"10.1016\/j.eprac.2024.11.017_bib16","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2165\/00002018-200427120-00002","article-title":"Combined thiazolidinedione-insulin therapy: should we be concerned about safety?","volume":"27","author":"Scheen","year":"2004","journal-title":"Drug Saf"},{"issue":"11","key":"10.1016\/j.eprac.2024.11.017_bib17","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMc1600827","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Sarafidis","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2024.11.017_bib18","first-page":"891","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"376","author":"Williams","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2024.11.017_bib19","first-page":"410","article-title":"Patients with type 2 diabetes and CV disease, empagliflozin reduces CV and all-cause mortality","volume":"93","author":"Ebell","year":"2016","journal-title":"Am Fam Physician"},{"issue":"3","key":"10.1016\/j.eprac.2024.11.017_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3350\/cmh.2022.0330","article-title":"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis","volume":"29","author":"Park","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"8","key":"10.1016\/j.eprac.2024.11.017_bib21","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2024.11.017_bib22","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.eprac.2024.11.017_bib23","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2024.11.017_bib24","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.eprac.2024.11.017_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12933-023-01877-6","article-title":"Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study","volume":"22","author":"Sohn","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.eprac.2024.11.017_bib26","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.eprac.2024.11.017_bib27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00592-021-01830-7","article-title":"Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: a network meta-analysis","volume":"59","author":"Ding","year":"2022","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.eprac.2024.11.017_bib28","volume":"14","author":"Gu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eprac.2024.11.017_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.923606","article-title":"GLP-1 RAs and SGLT-2 inhibitors for insulin resistance in nonalcoholic fatty liver disease: systematic review and network meta-analysis","volume":"13","author":"Yan","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eprac.2024.11.017_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1182037","article-title":"New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Kongmalai","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eprac.2024.11.017_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.017_bib32","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2024.11.017_bib33","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.eprac.2024.11.017_bib34","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/jrsm.1270","article-title":"Resolve conflicting rankings of outcomes in network meta-analysis: partial ordering of treatments","volume":"8","author":"R\u00fccker","year":"2017","journal-title":"Res Synth Methods"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.017_bib35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metabol"},{"issue":"11","key":"10.1016\/j.eprac.2024.11.017_bib36","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"issue":"9","key":"10.1016\/j.eprac.2024.11.017_bib37","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.eprac.2024.11.017_bib38","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.eprac.2024.11.017_bib39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol Commun"},{"issue":"10","key":"10.1016\/j.eprac.2024.11.017_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108610","article-title":"Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"37","author":"Shi","year":"2023","journal-title":"J\u00a0Diabetes Complicat"},{"key":"10.1016\/j.eprac.2024.11.017_bib41","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s13410-021-00980-2","article-title":"Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients","volume":"42","author":"Hussain","year":"2022","journal-title":"Int J Diabetes Dev Ctries"},{"key":"10.1016\/j.eprac.2024.11.017_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"10019","key":"10.1016\/j.eprac.2024.11.017_bib43","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.017_bib44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.eprac.2024.11.017_bib45","first-page":"3213","article-title":"One year's treatment with the glucagon-like peptide 1 receptor agonist liraglutide decreases hepatic fat content in women with nonalcoholic fatty liver disease and prior gestational diabetes mellitus in a randomized, placebo-controlled trial","volume":"9","author":"Vedtofte","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"12","key":"10.1016\/j.eprac.2024.11.017_bib46","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/dom.13007","article-title":"Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: a pilot randomized trial","volume":"19","author":"Khoo","year":"2017","journal-title":"Diabetes Obes Metabol"},{"issue":"5","key":"10.1016\/j.eprac.2024.11.017_bib47","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/liv.14065","article-title":"Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease","volume":"39","author":"Khoo","year":"2019","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.017_bib48","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.eprac.2024.11.017_bib49","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/met.2022.0014","article-title":"Effect of 5:2 fasting diet on liver fat content in patients with type 2 diabetic with nonalcoholic fatty liver disease","volume":"20","author":"Xiao","year":"2022","journal-title":"Metab Syndr Relat Disord"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.017_bib50","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/dom.15359","article-title":"Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: a randomized, open-label, controlled trial","volume":"26","author":"Fan","year":"2024","journal-title":"Diabetes Obes Metabol"},{"issue":"1","key":"10.1016\/j.eprac.2024.11.017_bib51","doi-asserted-by":"crossref","first-page":"e001990","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"10","key":"10.1016\/j.eprac.2024.11.017_bib52","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2024.11.017_bib53","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/jdi.13457","article-title":"Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone","volume":"12","author":"Cho","year":"2021","journal-title":"J\u00a0Diabetes Investig"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.017_bib54","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/dom.13061","article-title":"Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study","volume":"20","author":"Shibuya","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.017_bib55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3164\/jcbn.20-129","article-title":"Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study","volume":"68","author":"Tobita","year":"2021","journal-title":"J\u00a0Clin Biochem Nutr"},{"issue":"1","key":"10.1016\/j.eprac.2024.11.017_bib56","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12876-023-02948-4","article-title":"Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial","volume":"23","author":"Attaran","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.017_bib57","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/dom.15006","article-title":"Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: a prospective randomized study","volume":"25","author":"Hiruma","year":"2023","journal-title":"Diabetes Obes Metabol"},{"issue":"9","key":"10.1016\/j.eprac.2024.11.017_bib58","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.017_bib59","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J\u00a0Diabetes Investig"},{"issue":"12","key":"10.1016\/j.eprac.2024.11.017_bib60","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3390\/ph15121516","article-title":"The impact of an SGLT2 inhibitor versus ursodeoxycholic acid on liver steatosis in diabetic patients","volume":"15","author":"Elhini","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.eprac.2024.11.017_bib61","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.clinre.2020.01.007","article-title":"Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"44","author":"Zhang","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"10.1016\/j.eprac.2024.11.017_bib62","doi-asserted-by":"crossref","first-page":"e3292","DOI":"10.1002\/dmrr.3292","article-title":"Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"36","author":"Liu","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.017_bib63","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181304","article-title":"Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease","volume":"38","author":"Tian","year":"2018","journal-title":"Biosci Rep"},{"key":"10.1016\/j.eprac.2024.11.017_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1088187","article-title":"Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease","volume":"14","author":"Ying","year":"2023","journal-title":"Front Microbiol"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.017_bib65","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2024.11.017_bib66","doi-asserted-by":"crossref","DOI":"10.1100\/2012\/496453","article-title":"The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone","volume":"2012","author":"Ohki","year":"2012","journal-title":"ScientificWorldJournal"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.017_bib67","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jdi.12888","article-title":"Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial","volume":"10","author":"Feng","year":"2019","journal-title":"J\u00a0Diabetes Investig"},{"issue":"5","key":"10.1016\/j.eprac.2024.11.017_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104747","article-title":"Cryptogenic intracranial hemorrhagic strokes associated with hypervitaminosis E and acutely elevated \u03b1-tocopherol levels","volume":"29","author":"Le","year":"2020","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.eprac.2024.11.017_bib69","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.017_bib70","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/hep.28827","article-title":"Exenatide improves both hepatic and adipose tissue insulin resistance: a dynamic positron emission tomography study","volume":"64","author":"Gastaldelli","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2024.11.017_bib71","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12933-019-0954-6","article-title":"Liraglutide improves lipid\u00a0metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1\/2 pathway","volume":"18","author":"Wu","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.eprac.2024.11.017_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118457","article-title":"Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db\/db mice","volume":"261","author":"Liu","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.eprac.2024.11.017_bib73","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fphar.2020.00432","article-title":"Liraglutide attenuates non-alcoholic fatty liver disease in mice by regulating the local renin-angiotensin system","volume":"11","author":"Yang","year":"2020","journal-title":"Front Pharmacol"},{"issue":"22","key":"10.1016\/j.eprac.2024.11.017_bib74","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2024.11.017_bib75","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis","volume":"14","author":"Ong Lopez","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.eprac.2024.11.017_bib76","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing\u00a0the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.017_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020818","article-title":"Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE(-\/-) mice by\u00a0activating autophagy and reducing ER stress and apoptosis","volume":"22","author":"Nasiri-Ansari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eprac.2024.11.017_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106730","article-title":"Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-\u03b1, IL-1\u03b2, and IL-18 in rat liver","volume":"86","author":"ElMahdy","year":"2020","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.eprac.2024.11.017_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108503","article-title":"Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation","volume":"104","author":"Hazem","year":"2022","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.eprac.2024.11.017_bib80","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol Metab Syndrome"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.017_bib81","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.017_bib82","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2024.11.017_bib83","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.017_bib84","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A\u00a0phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"1116","key":"10.1016\/j.eprac.2024.11.017_bib85","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/postgradmedj-2018-135967","article-title":"Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"94","author":"Sridharan","year":"2018","journal-title":"Postgrad Med"},{"key":"10.1016\/j.eprac.2024.11.017_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.649018","article-title":"Efficacy of various hypoglycemic agents in the treatment of patients with nonalcoholic liver disease with or without diabetes: a network meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eprac.2024.11.017_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108294","article-title":"Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver\u00a0disease: a systematic review and network meta-analysis","volume":"240","author":"Theodoridis","year":"2022","journal-title":"Pharmacol Ther"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2400867X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2400867X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:42:06Z","timestamp":1744717326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2400867X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1530891X2400867X"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.11.017","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Protein-2 Inhibitors on Treating Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}